Molnupiravir sales have seen a secular decline through 2022, so that base effect is most likely permanently gone for Divis. Paxlovid is holding up better for Laurus, so may continue contributing for a few more Qs, although at lower %s.
| Subscribe To Our Free Newsletter |
